Colorado Springs Urological Associates (CSUA) Signed Definitive Agreement With Solaris Health to Join the Nation’s Largest Urological Services Provider

CSUA Seizes Innovation Opportunities Presented by Dynamic National Urology Platform Caring for More than One-Half Million Patients

Solaris Health Holdings announced today that Colorado Springs Urological Associates (CSUA), serving Colorado Springs, CO, and the surrounding area, has entered into a definitive agreement to join as an affiliate practice. Terms have not been disclosed.

The agreement with CSUA extends the reach of the national Solaris platform to the Mountain West. Solaris is the nation’s leading provider of independent urological services. CSUA will become the fifth urology practice this year to join Solaris.

CSUA is a union of two patient-centric, top-rated urological practices, tracing its roots back 50 years. Upon closing, the addition of CSUA means that Solaris now aligns the skills and talents of 345 providers who care for over 530,000 unique patients each year at more than 135 sites in New York, Ohio, Pennsylvania, Kentucky, Indiana, Illinois, Michigan, and Colorado. The deal is expected to close in Q4 of 2021.

“We welcome CSUA as a practice that shares our vision to develop a national practice predicated on clinical excellence and business best practices,” stated Solaris Chairman and Chief Ecosystem Officer Deepak A. Kapoor, MD. Solaris President, Gary M. Kirsh, MD added, “By choosing to scale nationally, CSUA physicians will maintain their high standards of patient care and gain access to the resources needed to successfully navigate an increasingly complex and consolidated health care system.”

CSUA Market President Jeffrey Moody, MD announced, “The doctors and staff of Colorado Springs Urological Associates are excited about our new partnership with Solaris Health. This brings an entirely new dimension of care, access, service, and technology to southern Colorado urology. We are thrilled to continue to advance the care we provide our community.”

Jeffrey Ferguson, MD, CSUA Director of Business Development and Strategy, added, “This partnership will give our team access to a national urology platform with expertise in clinical care and practice management and help us improve the service we provide to our patients and our community.” Dr. Ferguson will serve on the Solaris Board of Directors.

“The addition of Colorado Springs Urological Associates demonstrates that the appeal of our platform is not constrained by geography and represents a significant boost to the momentum we are building for even greater expansion,” said Eric Mason, MD, MBA, Solaris Health CEO.

McDermott Will & Emery LLP served as legal counsel to Solaris. Physician Growth Partners acted as exclusive financial advisor to CSUA and Lathrop GPM LLP served as legal counsel to CSUA.

New York-based Lee Equity Partners is a financial partner in Solaris.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”